Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data
出版年份 2023 全文链接
标题
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data
作者
关键词
-
出版物
CURRENT OPINION IN CARDIOLOGY
Volume 38, Issue 6, Pages 539-545
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2023-10-05
DOI
10.1097/hco.0000000000001084
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
- (2023) Ildiko Lingvay et al. Cardiovascular Diabetology
- Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison
- (2023) Carel W. le Roux et al. DIABETES OBESITY & METABOLISM
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
- (2023) W Timothy Garvey et al. LANCET
- Efficacy of tirzepatide 5, 10, and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison
- (2022) Karan Vadher et al. DIABETES OBESITY & METABOLISM
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
- (2022) Naveed Sattar et al. NATURE MEDICINE
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
- (2022) Amalia Gastaldelli et al. Lancet Diabetes & Endocrinology
- Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective
- (2022) Christophe De Block et al. DIABETES OBESITY & METABOLISM
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
- (2022) Nuha A. ElSayed et al. DIABETES CARE
- The Global Burden of Cardiovascular Diseases and Risk
- (2022) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
- (2022) Carel W. le Roux et al. Obesity
- The evolving story of incretins ( GIP and GLP ‐1) in metabolic and cardiovascular disease: A pathophysiological update
- (2021) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- The Dual GIP and GLP ‐1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Biomarkers in Patients with Type 2 Diabetes: a Post‐Hoc Analysis
- (2021) Jonathan M Wilson et al. DIABETES OBESITY & METABOLISM
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
- (2021) DIABETES CARE
- GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
- (2020) Yusaku Mori et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Using a reporter mouse to map known and novel sites of GLP-1 receptor expression in peripheral tissues of male mice
- (2020) Daniel B Andersen et al. ENDOCRINOLOGY
- Diabetes Remission Status During Seven-year Follow-up of the Longitudinal Assessment of Bariatric Surgery Study
- (2020) Jonathan Q Purnell et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
- (2020) Thinzar Min et al. Diabetes Therapy
- Mechanisms by which GLP-1 receptor agonists and SGLT-2 inhibitors reduce cardiovascular risk
- (2019) Abhinav Sharma et al. Canadian Journal of Diabetes
- Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
- (2019) Alice E. Adriaenssens et al. Cell Metabolism
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
- (2019) Lærke S. Gasbjerg et al. PEPTIDES
- GIP analogues and the treatment of obesity-diabetes
- (2019) Clifford J. Bailey PEPTIDES
- Physiological roles of the GIP receptor in murine brown adipose tissue
- (2019) Jacqueline L. Beaudry et al. Molecular Metabolism
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists
- (2015) Brian Finan et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
- (2014) Laurie L. Baggio et al. JOURNAL OF CLINICAL INVESTIGATION
- Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
- (2013) B. Finan et al. Science Translational Medicine
- GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
- (2011) N. Mentis et al. DIABETES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search